Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Comments

Loading...

Mydecine Innovations Gr Stock News

MYCOFOTCPK

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$0.00424

-0.00045-9.50%

At close: -

$0.0110

0.00631134.79%

Mydecine Innovations Gr (MYCOF) Forecast

News

Earnings Mydecine Innovations Gr (MYCOF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest Mydecine Innovations Gr Stock News | OTC:MYCOF | Benzinga

Get the latest news on Mydecine Innovations Gr stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Mydecine Innovations Gr performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Monday, October 28, 2024

Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises
Juan Spínelli

Wednesday, July 31, 2024

EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
Javier Hasse

Thursday, February 15, 2024

Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Lara Goldstein

Monday, October 16, 2023

Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More
Lara Goldstein

Thursday, October 12, 2023

Psychedelic-Based Drugs Biotech Company Begins Trading On UK's AQSE Growth Market
Nina Zdinjak

Monday, August 21, 2023

Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
Lara Goldstein

Tuesday, August 15, 2023

Mydecine Releases Q2 2023: Developer Of Smoke Cessation Psilocybin Prodrugs & MDMA Analogs
Lara Goldstein

Tuesday, August 01, 2023

Jamaica Launches Organic Psilocybin Gummies & New Psychedelic Retreat: Rose Hill's New Offer
Lara Goldstein

Wednesday, May 31, 2023

Mydecine's Prospectus Supplement Closing Under Share Subscription And Management Update
Lara Goldstein

Tuesday, May 23, 2023

Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More
Lara Goldstein

Wednesday, May 17, 2023

Mydecine's Q1 2023 Reports Shows Decline In Assets And R&D, Increase In Net Loss And Accumulated Deficit
Lara Goldstein

Monday, May 01, 2023

Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
Lara Goldstein

Tuesday, April 25, 2023

New Set Of MDMA Analogs To Hit The Clinic: These Are The Latest Positive Findings
Lara Goldstein

Monday, April 03, 2023

Mydecine: 2022 Financials & Business Update By Next-Gen Psychedelics Producer, Smoke Cessation Trial And More
Lara Goldstein

Wednesday, January 04, 2023

These Are The 11 Biggest Psychedelics News And Trends You May Have Missed Last Year
Lara Goldstein

Tuesday, December 20, 2022

Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
Lara Goldstein

Tuesday, December 13, 2022

Psychedelic Company Sale: Mydecine Gets Over $2.5M For Wholly-Owned Tech Subsidiary Business
Lara Goldstein

Tuesday, November 22, 2022

Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
Lara Goldstein

Tuesday, November 15, 2022

Mydecine's Q3 Financials & Update, Sustained Target On Smoking Cessation For Next 12 Months
Lara Goldstein

Monday, September 26, 2022

Psychedelics Biotechs Clearmind And Mydecine Share Consolidation And Subscription Agreements
Lara Goldstein

Friday, September 23, 2022

Will Cannabis Entrepreneurs Switch To Psychedelics?
Andrew Ward

Tuesday, August 30, 2022

World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory Council—Get To Know Them
Lara Goldstein

Friday, August 19, 2022

Mydecine Innovations Group Announces Private ...
Benzinga Newsdesk

Tuesday, August 16, 2022

Mydecine Innovations Group Reports Q2 Financial Results And Management Updates
Lara Goldstein

Thursday, July 21, 2022

Understanding The Psilocybin Supply Chain: Every Production Method Explained
Natan Ponieman

Tuesday, July 19, 2022

Two Psychedelic Companies File Patent Applications For Psilocybin And MDMA Analogues, Here's What Could Change
Lara Goldstein

Friday, June 17, 2022

Government-Funded Smoking Cessation Trial Uses Mydecine's New Psilocybin-Derived MYCO-001, Recently FDA-Approved
Lara Goldstein

Thursday, April 14, 2022

Mydecine Announces 1-for-50 Reverse Stock Split
Fermin Orgambide

Wednesday, April 06, 2022

Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More!
Natan Ponieman

Friday, April 01, 2022

Mydecine Reports Financial Results For 2021
Fermin Orgambide

Wednesday, February 09, 2022

Benzinga's Unprecedented Psychedelics Investing Conference Lands In Miami On April 19th
Benzinga Cannabis

Friday, December 17, 2021

Mind Medicine to Study Effect of Time on LSD Microdosing
InvestorBrandNetwork - Sponsored

Tuesday, November 16, 2021

Mydecine: Q3 Financials, Advances Research On Psychedelic Therapies For Mental Health & Addiction Disorders
Jelena Martinovic

Thursday, November 04, 2021

The Legacy Of Dr. Aaron Beck, Father Of Cognitive Therapy, Lives On In Psychedelic Medicine
Natan Ponieman

Wednesday, October 20, 2021

Historic: Federal Agency Awards Grant For Psychedelics Research, First Time In 50 years
Natan Ponieman

Monday, September 27, 2021

Mydecine On Verge Of Finalizing Spin-Out Of Cannabis Subsidiaries, Obtains Shareholder And Court Approval
Jelena Martinovic

Saturday, September 18, 2021

Mydecine Announces New Clinical Trial For Smoking Cessation
Microdose Psychedelic Insights

Monday, September 13, 2021

Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics
Natan Ponieman

Thursday, August 26, 2021

PharmaDrug Strikes Deal With Johns Hopkins University For A Clinical Trial Into Psychedelic DMT
Natan Ponieman

Monday, August 23, 2021

Psyched: Beckley Psytech Raises $80M, Diamond Therapeutics To Study Psilocybin Microdosing, Mydecine and Johns Hopkins Partner Up
Natan Ponieman

Wednesday, August 18, 2021

Mydecine Innovations Inks Deal With Johns Hopkins University To Undertake Psychedelics Research Into Smoking Cessation
Natan Ponieman

Tuesday, August 03, 2021

Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
Natan Ponieman

Friday, July 02, 2021

Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
Natan Ponieman

Wednesday, June 30, 2021

Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More
Natan Ponieman

Monday, June 21, 2021

Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform
Natan Ponieman

Thursday, June 17, 2021

Mydecine Identifies 4 Psychedelic-Related Drugs to Tackle the Mental Health Crisis
Shashank Jacob

Wednesday, June 16, 2021

Mydecine Innovations Group Launches AI-Assisted Drug Discovery Program
Natan Ponieman

Friday, May 28, 2021

Psyched: Nasdaq Gets Its Third Psychedelics Company, Mynd Goes Public, Delic Buys New Research Facility
Natan Ponieman

Wednesday, May 19, 2021

Mydecine To Spin-Out Its U.S. Cannabis Assets By Mid July
Jelena Martinovic

Popular Channels

PreMarket Playbook
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved